PriceTargets.com logo

BioHarvest Sciences - BHST Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.50
  • Forecasted Upside: 272.49%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.75 As of 09/15/2026 03:56 PM ET
▼ -0.055 (-3.06%)

This chart shows the closing price for BHST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioHarvest Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHST

Analyst Price Target is $6.50
▲ +272.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BioHarvest Sciences in the last 3 months. The average price target is $6.50, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 272.49% upside from the last price of $1.75.

This chart shows the closing price for BHST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in BioHarvest Sciences. This rating has held steady since March 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/15/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/14/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/12/2026Maxim GroupLower TargetBuy ➝ Buy$12.00 ➝ $5.00
8/12/2026Roth CapitalLower TargetBuy ➝ Buy$10.00 ➝ $8.00
6/18/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
6/3/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
2/19/2026Roth CapitalInitiated CoverageBuy$10.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/5/2025Craig HallumInitiated CoverageBuy$15.00
4/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
12/18/2024Maxim GroupInitiated CoverageBuy$12.00
12/6/2024HC WainwrightInitiated CoverageBuy ➝ Buy$14.00 ➝ $14.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BioHarvest Sciences logo
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Read More

Today's Range

Now: $1.75
Low: $1.62
High: $1.87

50 Day Range

MA: $2.19
Low: $1.80
High: $2.90

52 Week Range

Now: $1.75
Low: $1.62
High: $12.80

Volume

58,639 shs

Average Volume

37,346 shs

Market Capitalization

$34.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of BioHarvest Sciences?

The following Wall Street sell-side analysts have issued research reports on BioHarvest Sciences in the last twelve months: Maxim Group, Roth Capital, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for BHST.

What is the current price target for BioHarvest Sciences?

0 Wall Street analysts have set twelve-month price targets for BioHarvest Sciences in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 261.1%. Roth Capital has the highest price target set, predicting BHST will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for BioHarvest Sciences in the next year.
View the latest price targets for BHST.

What is the current consensus analyst rating for BioHarvest Sciences?

BioHarvest Sciences currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BHST, but not buy more shares or sell existing shares.
View the latest ratings for BHST.

What other companies compete with BioHarvest Sciences?

Other companies that are similar to BioHarvest Sciences include Medifast, Beauty Health, FitLife Brands, Lifevantage and Meiwu Technology. Learn More about companies similar to BioHarvest Sciences.

How do I contact BioHarvest Sciences' investor relations team?

BioHarvest Sciences' physical mailing address is 1140 - 625 HOWE STREET, VANCOUVER BC, V6C 2T6. The company's listed phone number is 646-863-2177 and its investor relations email address is [email protected]. The official website for BioHarvest Sciences is bioharvest.com. Learn More about contacing BioHarvest Sciences investor relations.